Princeton Alpha Management LP cut its stake in shares of Johnson & Johnson (NYSE:JNJ) by 4.3% during the first quarter, according to its most recent disclosure with the SEC. The institutional investor owned 23,953 shares of the company’s stock after selling 1,089 shares during the period. Johnson & Johnson comprises approximately 1.0% of Princeton Alpha Management LP’s investment portfolio, making the stock its 3rd largest position. Princeton Alpha Management LP’s holdings in Johnson & Johnson were worth $2,983,000 as of its most recent filing with the SEC.

Other institutional investors have also recently bought and sold shares of the company. Pittenger & Anderson Inc. raised its stake in shares of Johnson & Johnson by 2.5% in the fourth quarter. Pittenger & Anderson Inc. now owns 64,939 shares of the company’s stock valued at $7,482,000 after buying an additional 1,565 shares during the last quarter. IFM Investors Pty Ltd bought a new stake in shares of Johnson & Johnson during the fourth quarter valued at approximately $4,036,000. Heritage Way Advisors LLC bought a new stake in shares of Johnson & Johnson during the fourth quarter valued at approximately $2,119,000. Wall Street Access Asset Management LLC raised its stake in shares of Johnson & Johnson by 1.1% in the fourth quarter. Wall Street Access Asset Management LLC now owns 11,859 shares of the company’s stock valued at $1,366,000 after buying an additional 134 shares during the last quarter. Finally, LeJeune Puetz Investment Counsel LLC bought a new stake in shares of Johnson & Johnson during the fourth quarter valued at approximately $2,677,000. Hedge funds and other institutional investors own 65.98% of the company’s stock.

Johnson & Johnson (NYSE:JNJ) traded down 0.374% on Wednesday, reaching $131.715. 926,955 shares of the company’s stock were exchanged. The company has a 50 day moving average price of $132.91 and a 200-day moving average price of $127.75. Johnson & Johnson has a 1-year low of $109.32 and a 1-year high of $137.08. The company has a market capitalization of $353.52 billion, a PE ratio of 22.287 and a beta of 0.78.

Johnson & Johnson (NYSE:JNJ) last issued its earnings results on Tuesday, July 18th. The company reported $1.83 earnings per share for the quarter, topping the consensus estimate of $1.79 by $0.04. Johnson & Johnson had a return on equity of 21.58% and a net margin of 20.31%. The company had revenue of $18.84 billion for the quarter, compared to analyst estimates of $18.94 billion. During the same period in the prior year, the firm posted $1.74 EPS. The business’s revenue was up 1.9% compared to the same quarter last year. On average, equities research analysts anticipate that Johnson & Johnson will post $7.18 earnings per share for the current year.

The business also recently disclosed a quarterly dividend, which will be paid on Tuesday, September 12th. Stockholders of record on Tuesday, August 29th will be issued a dividend of $0.84 per share. This represents a $3.36 dividend on an annualized basis and a dividend yield of 2.54%. The ex-dividend date of this dividend is Friday, August 25th. Johnson & Johnson’s dividend payout ratio is 56.76%.

COPYRIGHT VIOLATION WARNING: This news story was originally published by The Cerbat Gem and is owned by of The Cerbat Gem. If you are accessing this news story on another publication, it was illegally stolen and reposted in violation of United States and international copyright & trademark law. The correct version of this news story can be viewed at https://www.thecerbatgem.com/2017/08/30/johnson-johnson-jnj-is-princeton-alpha-management-lps-3rd-largest-position.html.

Several equities research analysts recently commented on JNJ shares. UBS AG reissued a “buy” rating and issued a $136.00 price target on shares of Johnson & Johnson in a report on Monday, May 15th. Cowen and Company reissued a “buy” rating and issued a $143.00 price target (up previously from $138.00) on shares of Johnson & Johnson in a report on Friday, May 19th. Vetr raised shares of Johnson & Johnson from a “hold” rating to a “buy” rating and set a $132.33 price target for the company in a report on Thursday, May 18th. BMO Capital Markets reissued a “buy” rating and issued a $132.00 price target on shares of Johnson & Johnson in a report on Friday, June 2nd. Finally, Royal Bank Of Canada reaffirmed a “buy” rating and set a $128.00 target price on shares of Johnson & Johnson in a report on Thursday, June 15th. Four analysts have rated the stock with a sell rating, nine have assigned a hold rating and nine have given a buy rating to the stock. Johnson & Johnson has an average rating of “Hold” and a consensus target price of $133.91.

In other news, VP Dominic J. Caruso sold 82,591 shares of the stock in a transaction dated Thursday, July 20th. The stock was sold at an average price of $136.72, for a total transaction of $11,291,841.52. Following the transaction, the vice president now owns 226,693 shares of the company’s stock, valued at approximately $30,993,466.96. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, VP Paulus Stoffels sold 102,692 shares of the stock in a transaction dated Monday, July 24th. The shares were sold at an average price of $133.14, for a total value of $13,672,412.88. Following the transaction, the vice president now directly owns 230,342 shares in the company, valued at approximately $30,667,733.88. The disclosure for this sale can be found here. Corporate insiders own 0.19% of the company’s stock.

Johnson & Johnson Company Profile

Johnson & Johnson is a holding company, which is engaged in the research and development, manufacture and sale of a range of products in the healthcare field. It operates through three segments: Consumer, Pharmaceutical and Medical Devices. Its primary focus is products related to human health and well-being.

Want to see what other hedge funds are holding JNJ? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Johnson & Johnson (NYSE:JNJ).

Institutional Ownership by Quarter for Johnson & Johnson (NYSE:JNJ)

Receive News & Stock Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related stocks with our FREE daily email newsletter.